COMMUNIQUÉS West-GlobeNewswire

-
Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2023 Financial Results
28/02/2024 -
Prime Medicine to Participate in Upcoming Investor Conferences
28/02/2024 -
Recludix Pharma to Participate in Two Investor Conferences in March
28/02/2024 -
Spectral AI to Participate in Upcoming Investor Conferences
28/02/2024 -
NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate Update
28/02/2024 -
Corbus Pharmaceuticals Appoints Dr. Dominic Smethurst as Chief Medical Officer
28/02/2024 -
Ovid Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference
28/02/2024 -
Accolade To Present at Upcoming Investor Conferences
28/02/2024 -
Protara Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference
28/02/2024 -
Compass Therapeutics Announces Publication of CTX-8371 Preclinical Data in OncoImmunology, its Bispecific Antibody Checkpoint Inhibitor, now Advancing to First-in-Human Clinical Trial
28/02/2024 -
Smith+Nephew and U.S. Army Institute of Surgical Research to engage in Master Cooperative Research and Development Agreement
28/02/2024 -
Tonix Pharmaceuticals Completes Clinical Stage of Phase 1 Trial for TNX-1500 (Fc-modified humanized anti-CD40L mAb) in Healthy Volunteers
28/02/2024 -
Mestag Therapeutics to Present at Evercore ISI 2024 Emerging Biotech Conference
28/02/2024 -
ZyVersa Therapeutics Highlights Data from Review Article Published in Nature Reinforcing IC 100’s Rationale for Inhibiting ASC and ASC Specks to Attenuate Damaging Inflammation Associated with Various Conditions, Including Obesity and Its Complications
28/02/2024 -
Immunocore reports fourth quarter and full year 2023 financial results and provides a business update
28/02/2024 -
SPT Labtech and RevoluGen Demonstrate Fully Automated Bead-Based High Molecular Weight DNA Extraction
28/02/2024 -
Philips extends leadership in virtually helium-free MRI with more than 1,000 systems installed, expanding patient access worldwide
28/02/2024 -
Nexstim Receives NBS System 5 Order from Neurosurgery Customer in Germany
28/02/2024 -
PulseSight Therapeutics Launches to Advance Non-viral Gene Therapies with Disruptive Minimally-Invasive Delivery Technology for Severe Retinal Diseases
28/02/2024
Pages